The Office of Research Services has provided guidance to investigators to support IND / IDE applications to the FDA. Some examples are listed below.

**IND**
- Single-agent Amrubicin as second line therapy in patients with advanced/metastatic refractory urothelial carcinoma
- 68 Ga-DOTATOC PET imaging for the treatment of neuroendocrine tumors
- Siltuximab treatment for anhedonia in patients across a spectrum of mood and anxiety disorders

**IND EXEMPTION**
- Olanzapine administration for the treatment of post-discharge nausea and vomiting in patients receiving general anesthesia for ambulatory surgery
- Tranexamic Acid to decrease intraoperative blood loss, postoperative blood loss and postoperative blood transfusion incidence in patients with glenohumeral arthritis undergoing a total shoulder arthroplasty procedure
- Bupivacaine administration in patients with excessive tearing/epiphora secondary to decreased orbicularis oculi muscle tone

**IND SINGLE PATIENT**
- Benznidazole for the treatment of Chagas cardiomyopathy
- Selinexor (KPT-330) to treat a patient with recurrent ovarian cancer
- Dichlorphenamidine to treat hyperkalemic period paralysis

**IDE**
- Ekso™, ReWalk™ and the Indego® to assist walking for persons with neurological conditions such as spinal cord injury and multiple sclerosis LIGHTLink-CXL corneal cross-linking system for experimental treatment for keratoconus, ectasia and corneal ulcer
- Transcutaneous vagus nerve stimulation to treat pain in subjects with Gulf War Illness

Contact ORS for further consultation.